Biography

Christopher J.W. Coggeshall has focused his 40-plus years of practice on commercial real estate transactions, including negotiating, structuring, and documenting commercial, retail, and industrial developments, shopping centers, office and apartment buildings, and industrial parks.

He has an extensive practice in drafting and negotiating commercial leases, acquisition documents, and government-assisted financings.

Services/Industries

Education

  • Harvard Law School  (LL.B.)
  • Cornell University  (B.Met.E.)

Bar Admissions

  • Maine
  • New Hampshire

Honors

  • AV® rated by Martindale-Hubbell
  • Recognized in Chambers USA: America's Leading Lawyers for Business under Real Estate
  • Named the Best Lawyers® 2013 and 2018 Real Estate "Lawyer of the Year" in Portland, Maine
  • Listed in The Best Lawyers in America© for Real Estate Law in Portland, Maine
  • Selected by peers for inclusion in New England Super Lawyers© under Real Estate

To learn more about third-party ratings and rankings, and the selection processes used for inclusion, click here.

Firm Highlights

Publication/Podcast

PPP: How is Maine Faring?

Originally enacted on March 27, the Paycheck Protection Program (PPP) offers loan support and (potentially) loan forgiveness to qualifying small businesses – generally defined as those with not more than 500 employees. According to...

News

Paycheck Protection Program Focuses on Short-Term and Misses Long-Term Damages

On June 8, the Portland Press Herald published an article, "Revamped emergency loan program remains a short-term fix," discussing the Paycheck Protection Program's (PPP) extended deadlines and loosened restrictions, but lack of solutions to...

Matter

Political Service

Mayor, City of Portland (2005-2006) Portland City Council (2002-2008) Portland City Council Transportation Committee, Chair (2002-2005) Jetport Master Planning Committee, Chair (2005-2007) Greater Portland Transit District, Trustee (2002-2005) Narrow Gauge Rail Alignment Committee, Chair...

News

Verrill Welcomes Esteemed Corporate and Securities Attorney Edward Rosenthal

(June 10, 2020) – Verrill is pleased to welcome corporate and securities attorney Edward Rosenthal to the firm as a member of the Business Law Group. Rosenthal brings with him more than 40 years...

Blog

IRS Issues New Guidance on CARES Act Retirement Plan Distributions and Loans

The IRS recently issued Notice 2020-50 , which expands relief provided for retirement plan distributions and loans under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Distributions Under the CARES Act, a...

Blog

IRS Allows Tax-Advantaged Leave Donation to COVID-19 Relief Organizations

Under new guidance, the IRS will give favorable tax treatment to employees who donate leave to COVID-19 relief organizations. In IRS Notice 2020-46 , the agency announced that employees who donate paid leave for...

Event

2020 OHRP Exploratory Workshop

Health care attorney Emily Fogler will be presenting at the 2020 OHRP Exploratory Workshop in the third session, discussing sharing responsibilities and protecting participants - redefining roles in the single IRB era. Stay tuned...

Matter

Community Service

Portland Regional Chamber, Chair (2012-14) Trustee (2008-16; 2019- present) Portland Community Chamber of Commerce, President (2019- ) Trustee (2016-present) Maine State Chamber of Commerce, Trustee (2009 - present) Project Green Schools, Advisory Trustee (2017-present...

Blog

Financial Institutions . . . In the News

Town & Country Federal Credit Union to host virtual money conference ( Mainebiz 6.23.2020) Connected Credit Union and Winslow Community Federal Credit Union ’s merger is effective June 27 and will be known as...

Publication/Podcast

FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...